Cover Image

Cost of decentralized CAR T-cell production in an academic nonprofit setting

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy with high acquisition costs, and it has raised concerns about affordability and sustainability in many countries. Furthermore, the current centralized production paradigm for the T cells is less than satisfactory. Therefore,...

Full description

Saved in:
Bibliographic Details
Main Authors: Ran, Tao (Author) , Eichmüller, Stefan B. (Author) , Schmidt, Patrick (Author) , Schlander, Michael (Author)
Format: Article (Journal)
Language:English
Published: 14 June 2020
In: International journal of cancer
Year: 2020, Volume: 147, Issue: 12, Pages: 3438-3445
ISSN:1097-0215
DOI:https://doi.org/10.1002/ijc.33156
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/https://doi.org/10.1002/ijc.33156
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.33156
Get full text
Author Notes:Tao Ran, Stefan B. Eichmüller, Patrick Schmidt, Michael Schlander

MARC

LEADER 00000caa a2200000 c 4500
001 1757268278
003 DE-627
005 20251110110244.0
007 cr uuu---uuuuu
008 210506s2020 xx |||||o 00| ||eng c
024 7 |a 10.1002/ijc.33156  |2 doi 
035 |a (DE-627)1757268278 
035 |a (DE-599)KXP1757268278 
035 |a (OCoLC)1341408376 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ran, Tao  |e VerfasserIn  |0 (DE-588)1018353518  |0 (DE-627)681066768  |0 (DE-576)355651149  |4 aut 
245 1 0 |a Cost of decentralized CAR T-cell production in an academic nonprofit setting  |c Tao Ran, Stefan B. Eichmüller, Patrick Schmidt, Michael Schlander 
264 1 |c 14 June 2020 
300 |a 8 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 06.05.2021 
520 |a Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy with high acquisition costs, and it has raised concerns about affordability and sustainability in many countries. Furthermore, the current centralized production paradigm for the T cells is less than satisfactory. Therefore, several countries are exploring alternative T-cell production modes. Our study is based on the T-cell production experience in a nonprofit setting in Germany. We first identified the work steps and main activities in the production process. Then we determined the fixed costs and variable costs. Main cost components included personnel and technician salaries, expenditure on equipment, a clean room, as well as production materials. All costs were calculated in 2018 euros and converted into U.S. dollars. For a clean room with one machine for closed and automated manufacturing installed, annual fixed costs summed up to approximately €438 098 ($584 131). The variable cost per production was roughly €34 798 ($46 397). At the maximum capacity of one machine, total cost per product would be close to €60 000 ($78 849). As shown in the scenario analysis, if three machines were to be installed in the clean room, per production cost could be as low as €45 000 (roughly $59905). If a cheaper alternative to lentivirus was used, per production total cost could be further reduced to approximately €33 000 (roughly $44309). Decentralized T-cell production might be a less costly and more efficient alternative to the current centralized production mode that requires a high acquisition cost. 
650 4 |a CAR-T cell therapy 
650 4 |a costs 
650 4 |a good manufacturing practice 
650 4 |a price 
650 4 |a T-cell production 
700 1 |a Eichmüller, Stefan B.  |d 1960-  |e VerfasserIn  |0 (DE-588)1025289226  |0 (DE-627)721986951  |0 (DE-576)37016704X  |4 aut 
700 1 |a Schmidt, Patrick  |d 1978-  |e VerfasserIn  |0 (DE-588)136916740  |0 (DE-627)588336491  |0 (DE-576)301343683  |4 aut 
700 1 |a Schlander, Michael  |d 1959-  |e VerfasserIn  |0 (DE-588)1036904652  |0 (DE-627)751411957  |0 (DE-576)389587710  |4 aut 
773 0 8 |i Enthalten in  |t International journal of cancer  |d Bognor Regis : Wiley-Liss, 1966  |g 147(2020), 12, Seite 3438-3445  |h Online-Ressource  |w (DE-627)269532781  |w (DE-600)1474822-8  |w (DE-576)079876129  |x 1097-0215  |7 nnas  |a Cost of decentralized CAR T-cell production in an academic nonprofit setting 
773 1 8 |g volume:147  |g year:2020  |g number:12  |g pages:3438-3445  |g extent:8  |a Cost of decentralized CAR T-cell production in an academic nonprofit setting 
787 0 8 |i Ergänzung  |a Schmitt, Michael, 1966 -   |t Comments on “Cost of decentralized CAR T cell production in an academic non-profit setting”  |d 2021  |w (DE-627)1940723345 
856 4 0 |u https://doi.org/https://doi.org/10.1002/ijc.33156  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.33156  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210506 
993 |a Article 
994 |a 2020 
998 |g 136916740  |a Schmidt, Patrick  |m 136916740:Schmidt, Patrick  |d 910000  |d 910100  |e 910000PS136916740  |e 910100PS136916740  |k 0/910000/  |k 1/910000/910100/  |p 3 
998 |g 1025289226  |a Eichmüller, Stefan B.  |m 1025289226:Eichmüller, Stefan B.  |d 140000  |d 60000  |e 140000PE1025289226  |e 60000PE1025289226  |k 0/140000/  |k 0/60000/  |p 2 
999 |a KXP-PPN1757268278  |e 3924527997 
BIB |a Y 
SER |a journal 
JSO |a {"relHost":[{"part":{"text":"147(2020), 12, Seite 3438-3445","extent":"8","pages":"3438-3445","volume":"147","year":"2020","issue":"12"},"pubHistory":["1.1966 -"],"note":["Gesehen am 28.02.08","Darin: Predictive oncology"],"titleAlt":[{"title":"Predictive oncology"}],"id":{"zdb":["1474822-8"],"issn":["1097-0215"],"eki":["269532781"],"doi":["10.1002/(ISSN)1097-0215"]},"origin":[{"dateIssuedDisp":"1966-","dateIssuedKey":"1966","publisher":"Wiley-Liss","publisherPlace":"Bognor Regis"}],"disp":"Cost of decentralized CAR T-cell production in an academic nonprofit settingInternational journal of cancer","recId":"269532781","title":[{"title_sort":"International journal of cancer","title":"International journal of cancer","subtitle":"publication of the International Union against Cancer (UICC) = Journal international du cancer"}],"titleTranslated":[{"translated":"Journal international du cancer"}],"language":["eng"],"physDesc":[{"extent":"Online-Ressource"}],"type":{"media":"Online-Ressource","bibl":"periodical"},"corporate":[{"display":"International Union against Cancer","role":"isb"}]}],"note":["Gesehen am 06.05.2021"],"name":{"displayForm":["Tao Ran, Stefan B. Eichmüller, Patrick Schmidt, Michael Schlander"]},"recId":"1757268278","id":{"doi":["10.1002/ijc.33156"],"eki":["1757268278"]},"origin":[{"dateIssuedDisp":"14 June 2020","dateIssuedKey":"2020"}],"language":["eng"],"physDesc":[{"extent":"8 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"person":[{"given":"Tao","role":"aut","family":"Ran","display":"Ran, Tao"},{"role":"aut","given":"Stefan B.","family":"Eichmüller","display":"Eichmüller, Stefan B."},{"display":"Schmidt, Patrick","family":"Schmidt","given":"Patrick","role":"aut"},{"display":"Schlander, Michael","role":"aut","given":"Michael","family":"Schlander"}],"title":[{"title_sort":"Cost of decentralized CAR T-cell production in an academic nonprofit setting","title":"Cost of decentralized CAR T-cell production in an academic nonprofit setting"}]} 
SRT |a RANTAOEICHCOSTOFDECE1420 

Similar Items